Broad-Spectrum Antiviral Drugs for Coronaviruses
- Broad-spectrum antiviral drugs may lower the vulnerability of public health systems to the coronavirus pandemic.
- Broad-spectrum antiviral drugs are needed to
- Combat the emergence of novel coronaviruses, e.g., COVID-19;
- Prevent the re-emergence of SARS-CoV, its mutants, and other related viruses;
- Combat the continuance of MERS-CoV infections (Totura and Bavari, 2019).
- Experiences from SARS and MERS outbreaks have revealed the demands for drugs with pan-coronavirus antiviral activities.
Antiviral Strategies for Coronaviruses
- Nucleoside analogues may have antiviral effects against SARS-CoV (Chu et al., 2006).
- Methods can be developed to antagonize viral nonstructural proteins (Totura and Bavari, 2019).
- Agents can be designed to neutralize structural proteins of the coronaviruses.
- Approaches can be developed to modulate essential host elements of viral infections.
Chu, C. K., Gadthula, S., Chen, X., Choo, H., Olgen, S., Barnard, D. L., & Sidwell, R. W. (2006). Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV). Antiviral Chemistry & Chemotherapy, 17(5), 285–289. https://doi.org/10.1177/095632020601700506
Totura, A. L., & Bavari, S. (2019). Broad-spectrum coronavirus antiviral drug discovery. Expert Opinion on Drug Discovery, 14(4), 397–412. https://doi.org/10.1080/17460441.2019.1581171